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Abstract: Background: The management of prosthetic joint infections (PJI) with debridement and
retention of the implant (DAIR) has its rules. Some authors claim that lacking the exchange
of mobile prosthetic parts is doomed to failure, while others regard it as optional. Methods:
Single-center retrospective cohort in PJIs treated with DAIR. Results: We included 112 PJIs (69 total
hip arthroplasties, 9 medullary hip prostheses, 41 total knee arthroplasties, and 1 total shoulder
arthroplasty) in 112 patients (median age 75 years, 52 females (46%), 31 (28%) immune-suppressed)
and performed a DAIR procedure in all cases—48 (43%) with exchange of mobile parts and 64 without.
After a median follow-up of 3.3 years, 94 patients (84%) remained in remission. In multivariate Cox
regression analysis, remission was unrelated to PJI localization, pathogens, number of surgical
lavages, duration of total antibiotic treatment or intravenous therapy, choice of antibiotic agents,
immune-suppression, or age. In contrast, the exchange of mobile parts was protective (hazard ratio
1.9; 95% confidence interval 1.2–2.9). Conclusions: In our retrospective single-center cohort, changing
mobile parts of PJI during the DAIR approach almost doubled the probability for long-term remission.
Keywords: antibiotic duration; DAIR; treatment failure; mobile parts’ exchange; orthopaedic surgery
1. Introduction
Prosthetic joint infection (PJI) management requires both surgery and antimicrobial therapy. The
surgical options include one- or two-stage implant exchange, resection arthroplasty (with or without
arthrodesis), or DAIR (debridement, antibiotics, irrigation, and retention). DAIR itself can have two
goals: cure [1,2] or (life-long) suppressive therapy. For curative DAIR, literature is sparse regarding
the number of surgical lavages needed [3] and the scientific proof for the recommended exchange of
mobile parts (polyethylene, liners) [4]. These are important questions, because the consequences may
lead to added expenses, prolongation of surgery (thus potentially enhancing surgical site infections [5]),
and increased morbidity [4]. In this study, we epidemiologically determine the role of mobile parts’
exchange in the remission of DAIR.
2. Methods
Geneva University Hospitals are the only public hospital system in Geneva and some parts of
neighboring France, with decades of experience in treating PJIs. In the DAIR approach, the exchange
of mobile parts is recommended but finally left to surgeons’ decision and skills.
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We have performed a retrospective cohort study with our DAIR approaches since 2004. Most
of the patients reported in this side study also participated in prospective studies [6–9] and in the
Geneva Arthroplasty Register [10]. We reported the PJI definition in prior publications [1,11,12], which
are based on the Infectious Diseases Society of America (IDSA) definitions [13]. A PJI required the
presence of intraoperative pus and/or several positive intraoperative microbiological samplings. We
considered remission as the absence of any clinical, laboratory, or imaging evidence of recurrence of
the original infection. For this study, we excluded cases with incomplete documentation, minimal
follow-up for less than 6 months, special pathogens such as mycobacteria or fungi, recurrent PJIs,
surgery with complete explantation, or cases that we did not treat by ourselves.
The indication for the DAIR approach accorded with international recommendations, e.g., the
presence of relatively susceptible pathogens, the absence of a sinus tract, sufficient soft tissue coverage,
the absence of implant loosening, and an acute infection [13]. We thus excluded chronic PJIs and those
with sinus tracts or prosthesis loosening and performed DAIR in acute surgical site infections [5] or
acute PJI’s in terms of late hematogenous seedings [1]. There were no chronic low-grade smoldering
PJIs in our study population. DAIR, by itself and its definition, implies to keep the fixed parts (with its
eventual prior cementation) in situ and to exchange only the mobile parts, if ever. We do not change
the cement or introduce a new one during the DAIR procedure. The indication for the exchange of
mobile parts (i.e., head, glenosphere, and polyethylene or metallic liner) depended on the surgeon, the
IDSA recommendations [13], and the availability of these mobile parts (which usually differ from one
commercial product to another).
After discharge, the patients were followed-up in our hospital or by an Infectious Diseases expert
in close collaboration (DL). We included the last patient on 10 October 2017 and continued the general
follow-up until 31 December 2018. We also performed a literature review regarding mobile parts’
exchange in DAIR, by including all available reports of the last twenty years that provide original data
with more than 10 own cases, and by excluding subsequent publications of the same database.
Statistical Analyses
We performed retrospective group comparisons using the Pearson-χ2, the Wilcoxon rank-sum
tests, and Kaplan–Meier curves for the entire study population, and repeated them for the subgroup
of patients with at least two years of clinical active medical follow-up. Cox regression determined
associations with remission. We introduced independent variables known to be associated with a
poor DAIR prognosis into the multivariate analysis, except for surgical interventions and antibiotic
treatment, which we automatically included into the final model. Likewise, we analyzed the number
of surgical lavages and the duration of antibiotic therapy as continuous and as categorical variables.
We included eight predictor variables per outcome and checked key variables for interaction. We used
STATA software (9.0, STATA™, College Station, TX, USA). P values ≤ 0.05 (two-tailed) were significant.
3. Results
3.1. Patients and Pathogens
Among 154 DAIR episodes treated in our center, we excluded 42 for various reasons (Figure 1).
We finally analyzed 112 PJIs (69 total hip arthroplasties, 9 medullary hip prostheses, 41 total
knee arthroplasties (of which 3 were rotational), and 1 total shoulder arthroplasty) in 112 patients
(median age 75 years, 52 females (46%), 31 (28%) immune-suppressed, and 23 (21%) bacteremic).
Overall, 33 arthroplasties were revisions of prior non-infected surgeries. The immune-suppressions
were as follows: diabetes mellitus (n = 13), alcoholism (n = 7), cancer (n =5), cirrhosis CHILD C
(n = 2), medications (n = 2), or mixed causes (n = 2). The median time delay between arthroplasty
(implantation) and infection was 4.3 months (range, 0.5–120 months). We detected 46 different
microbiological PJI patterns. The most frequently identified pathogens were Staphylococcus aureus
(n = 29; 8 methicillin-resistant), skin commensals (coagulase-negative staphylococci, corynebacteria,
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micrococci, Propionibacterium acnes; n = 32), streptococci (n = 22), Gram-negatives (n = 16; 3 Pseudomonas
aeruginosa), enterococci (n = 6), and polymicrobial PJIs (n = 12). Six episodes were culture-negative.
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3.2. Treatment
Overall, 108 DAIR cases (96%) were intended for cure. Suppressive DAIR was intended only in
four cases. The median number of surgical interventions for infection was 2 (range, 0–6), among
which there was an exchange of mobile parts in 48 cases (43%). The median duration of total
antibiotic treatment was 3 months (range, 1.5–6 months), with a median of 12 first days intravenously
(range, 0–49 days). We used 62 different antibiotic regimens with the five most frequent drugs being
vancomycin (n = 47), quinolones (n = 55), clindamycin (n = 27), amoxicillin/clavulanate (n = 20), and
rifampicin (n = 55). The antibiotics provoked important side effects in 36 patients (32%), of which nine
required the immediate stop of the medication: diarrhea (n = 14), nausea (n = 8), skin rash (n = 4),
acute renal insufficiency (n = 3), or various other events such as transient hepatitis or mycosis. These
adverse events occurred early in the course with a median delay of three weeks from the start.
3.3. Outcomes
After a median follow-up of 3.3 years (range, 1.9–7.7 years), a total of 94 patients (94/112; 84%)
remained in remission. Eighteen episodes (16%) witnessed septic failures occurring after a median
delay of 0.9 years (range, 0.5–1.5 years) following the first infection. Among these 18 failures, 11
were true microbiological recurrences with the initial pathogens and 7 were new infections. We
ignored non-infectious failures. In group comparison (Table 1), remission was unrelated to prosthesis
localization, pathogens, number of surgical debridements, duration of total antibiotic treatment and of
intravenous therapy, choice of antibiotic agents, immune-suppression, or age. The same proportions
were witnessed when analyzing only the subgroup of patients with a minimum of two years of
active clinical follow-up (Table 2). In this subgroup of 85 episodes, 13 (15%) witnessed failures.
Remission was still unrelated to prosthesis localization, pathogens, number of surgical debridements,
immune-suppression, or age. The multivariate analysis confirmed our group comparisons (Table 3).
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Table 1. Comparison of demographic, clinical, and treatment characteristics of patients with the
debridement and retention of the implant (DAIR) approach for prosthetic joint infections (PJI).
Remission Clinical Failure
Total n = 112 n = 94 p value * n = 18
Female sex 46 (49%) 0.224 6 (33%)
Age (median) 75 years 0.601 72 years
American Society of Anesthesiologists’ score (median) 3 points 0.991 3 points
Pain score on admission (median) 5 points 0.610 4 points
Total hip prostheses 58 (62%) 0.962 11 (61%)
Prior revision arthroplasty 26 (28%) 0.338 7 (39%)
Bacteremic infection 18 (19%) 0.406 5 (28%)
Infection due to Staphylococcus aureus 26 (28%) 0.329 3 (17%)
-Infection due to MRSA 8 (9%) 0.199 0 (0%)
-Infection due to streptococci 21 (22%) 0.101 1 (6%)
-Infection due to skin commensals 26 (28%) 0.625 6 (33%)
-Infection due to enterococci 4 (4%) 0.237 2 (11%)
-Infection due to gram-negative pathogens 11 (12%) 0.440 1 (6%)
Immune suppression + 27 (29%) 0.572 4 (22%)
Number of surgical interventions (median) 2 0.973 2
-more than 1 intervention 49 (52%) 0.869 9 (50%)
-exchange of mobile parts 40 (43%) 0.882 8 (44%)
Duration of antibiotic treatment (median) 90 days 0.224 98 days
-100 days compared to ≤ 100 days 30 (32%) 0.304 8 (44%)
Duration of intravenous treatment (median) 10 days 0.416 14 days
-7 days compared to ≤ 7 days 61 (65%) 0.125 15 (83%)
Use of rifampicin-ciprofloxacin combination 46 (49%) 0.934 9 (50%)
Use of clindamycin 24 (26%) 0.420 3 (17%)
Use of amoxicillin/clavulanate 17 (18%) 0.886 3 (17%)
Use of vancomycin 38 (40%) 0.451 9 (50%)
Immune suppression = corticosteroid medication, organ transplantation, advanced cirrhosis, diabetes mellitus,
alcoholism, or active cancer. MRSA = methicillin-resistant Staphylococcus aureus; DAIR = debridement, antibiotics,
irrigation, and retention; PJI = prosthetic joint infection.
Table 2. Comparisons for the subset of 85 episodes with at least two years of active follow-up.
Remission Clinical Failure
Total n = 85 n = 72 (85%) p value n = 13 (15%)
Female sex 35 (49%) 0.500 5 (38%)
Age (median) 73 years 0.840 73 years
Immune suppression + 25 (35%) 0.411 3 (23%)
Number of surgical
interventions (median) 2 0.598 2
Exchange of mobile parts 26 (36%) 0.492 6 (46%)
+ Immune suppression = corticosteroid medication, organ transplantation, advanced cirrhosis, diabetes mellitus,
alcoholism, or active cancer.
Table 3. Univariate and multivariate analyses of factors potentially related to remission of retained
infected arthroplasties (results expressed as hazard ratios with 95% confidence intervals).
Total n= 112 Univariate Analysis Multivariate Analysis
Female sex 0.8, 0.5–1.3 n.d.
Age (median) 1.0, 1.0–1.0 n.d.
American Society of Anesthesiologists’ score (median) 0.9, 0.7–1,2 n.d.
-ASA score 2 compared to 1 1.0, 0.8–1.3 n.d.
-ASA score 3 compared to 1 1.4, 0.5–4.0 n.d.
-ASA score 4 compared to 1 1.2, 0.4–3.5 n.d.
Pain score on admission (median) 1.1, 0.3–3.5 n.d.
Total hip prostheses 0.8, 0.5–1.2 n.d.
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Table 3. Cont.
Total n= 112 Univariate Analysis Multivariate Analysis
Revision arthroplasty 0.8, 0.5–1.3 n.d.
Bacteremic infection 1.3, 0.7–2.1 n.d.
Infection due to Staphylococcus aureus 1.0, 0.6–1.5 n.d.
-Infection due to MRSA 1.0, 0.5–2.1 1.1, 0.5–2.3
Infection due to streptococci 1.3, 0.8–2.1 n.d.
Infection due to enterococci 1.2, 0.4–3.4 n.d.
Number of surgical interventions (median) 0.8, 0.6–1.0 0.7, 0.5–1.1
-more than 1 intervention 0.7, 0.5–1.1 n.d.
-exchange of mobile parts 2.0, 1.3–3.0 1.9, 1.2–2.9
Duration of antibiotic treatment (median) 1.0, 1.0–1.0 1.0, 1.0–1.0
-100 days compared to ≤ 100 days 1.6, 0.9–2.5 n.d.
Duration of intravenous treatment (median) 1.0, 1.0–1.0 n.d.
-7 days compared to ≤ 7 days 0.8, 0.5–1.2 n.d.
Use of rifampicin-ciprofloxacin combination 1.2, 0.8–1.8 n.d.
* Significant values ≤ 0.05 (two-tailed) are displayed in bold and italic. MRSA = methicillin-resistant Staphylococcus
aureus, ASA = American Society of Anesthesiologists’ score, n.d. = not done.
In contrast, the exchange of mobile prosthetic parts was statistically protective. We saw this effect
when analyzing all 18 failures (hazard ratio 1.9, 95% confidence interval 1.2–2.9) or when regarding
only microbiological cure rates (excluding the 7 failures with new pathogens) (hazard ratio 1.7, 95%
CI 1.1–2.6). As expected, the Kaplan–Meier curve confirmed our significant findings only for the
period of the first 400 days. Thereafter, the curves paralleled each other with almost no differences
after 1000 days (Figure 2). We summarize our literature review (role of mobile parts’ exchange) in Table 4.
Table 4. Prosthetic joint infections treated with DAIR—selected articles with at least 10 own cases;
published since 1997.
Author NumberPJI
Main
Pathogen
Identified Key
Variables for Success
Exchange
Mobile Parts
Remission Incidence
and Remarks
Mont et al. [14] 24knees S. aureus Early PJI 24 (100%) 83%
Marculescu et al. [15] 99 S. aureus Early PJI (< 8 days),absence fistula 48 (48%) 46%
Deirmengian et al. [16] 31 S. aureus Lack of S. aureus 10 (32%) 35%, exchange nobenefice
Theis et al. [17] 73 S. aureus Early PJI (< 4 weeks) not reported 69%
Tsumura et al. [18] 10 S. aureus none 0 (0%) 80%
Grammatopoulos [19] 122 hips S. aureus Mobile parts’ exchange,(< 6 weeks) 65 (53%)
68%, four-fold
benefice of exchanging
Buller et al. [20] 309 Gram-positives Early PJI (< 3 weeks) 309 (100%) 52%
Gardner et al. [21] 44knees S. aureus none 44 (100%) 43%
Vilchez et al. [22] 53 S. aureus Serum CRP < 22 mg/L, 1debridement not reported 76%
Koyonos et al. [23] 138 S. aureus S. aureus not reported 35%
Puhto et al. [24] 113 staphylococci Leukocyte count < 10G/L not reported 62%
Peel et al. [25] 43 MRSA >1 debridement,antibiotics <3 months 18 (42%)
86%, exchange no
benefice
Achermann et al. [26] 50 staphylococci Early PJI (< 3 weeks) 26 (52%) 92%, exchange nobenefice
Achermann et al. [26] 50 staphylococci Early PJI (< 3 weeks) 26 (52%) 92%, exchange nobenefice
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Table 4. Cont.
Author NumberPJI
Main
Pathogen
Identified Key
Variables for Success
Exchange
Mobile Parts
Remission Incidence
and Remarks
Sukeik et al. [27] 26 hips staphylococci Early PJI (< 5 days) 26 (100%) 77%
Westberg et al. [28] 38 S. aureus Serum CRP < 10 mg/L not reported 71%
Geurts et al. [29] 89 S. aureus Early PJI (< 4 weeks) 0 (0%) 83%
Kuiper et al. [30] 91 staphylococci Coagulase-negativestaphylococci not reported 66%
Fehring et al. [17] 86 S. aureus none not reported 37%
Moojen et al. [3] 68 hips S. aureus none not reported 79%
Konigsberg et al. [31] 42 staphylococci Lack of S. aureus 42 (100%) 76%
Duque et al. [32] 67 S. aureus not MRSA and not P.aeruginosa 67 (100%) 69%
Sendi et al. [33] 30 hips staphylococci none 14 (47%) 90%
Lora-Tamayo et al. [34] 444 streptococci Mobile parts’ exchange 220 (50%) 58%, two-fold beneficeof exchanging
Chaussade et al. [1] 87 S. aureus Lack of MRSA 87 (100%) 69%
Rodriguez-Pardo [35] 174 Gram-negatives Ciprofloxacin treatment 96 (55%) 68%, exchange nobenefice
Choi et al. [36] 28 hips S. aureus Lack of S. aureus 19 (68%) 50%, exchange nobenefice
Choi et al. [37] 32knees S. aureus Mobile parts’ exchange 19 (59%)
31%, three-fold
benefice of exchanging
Present study 112 S. aureus Mobile parts’ exchange 48 (43%) 84%, two-fold benefice ofexchanging
DAIR = debridement, antibiotics, irrigation, and retention; MRSA = methicillin-resistant S. aureus; ASA = American
Society of Anesthesiologists’ score; PJI = prosthetic joint infection; CRP, C-reactive protein.
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4. Discussion
According to our cohort, changing of mobile parts of PJI during the DAIR approach increases
the probability of long-term remission, independently of if we had a follow-up of one year or
beyond two years. This effect was seen in the multivariate analysis, whereas we failed to reveal it
significantly in crude group comparisons with a huge case-mix. Surprisingly, despite worldwide expert
recommendations and international consensus [4,19], a scientific evaluation regarding this topic is
sparse and inconclusive. Some authors deny an influence on the final outcome [19,25,26,29,35,36], while
others systematically demand it [4,14,20,21,27,31,32]. According to their own publications, however,
their compliance in performing these exchanges oscillates around 50%, or they simply do not report
them [2] (Table 3). In our study, the hazard ratio in terms of benefice of the mobile parts’ exchange was
almost two, as it was equally witnessed in the multicenter study of Lora-Tamayo et al. [34]. Choi et al.
computed a potential three-fold benefice when performing polyethylene exchanges in infected knee
arthroplasties [37], while colleagues from Oxford report a four-fold increase in hip PJIs, especially
when infections were early with shorter than 6 weeks’ incubation period [19]. Of note, our indications
for the DAIR approach are based on internationally accepted recommendations [13].
We could not detect other variables associated with remission. The duration of antibiotic
prescription did not influence long-term success. Several authors’ groups reported remissions with
“short” prescriptions of 6 weeks in DAIR [1,2,14,16,18,28,38]. Others advocated for even less in selected
cases with excellent evolutions, such as three [18] or four weeks [29,37], suggesting that the antibiotic
duration per se is not determinant in DAIR when surgery has been adequately performed. This is
important, because every third patient in our cohort reported adverse events during the antibiotic
course [12].
Besides the fact that our single-center study is retrospective, it has other limitations. First, the
proportion of “curative” DAIR cases was very high (96%). These patients are foreseen to stop antibiotics
after several weeks of treatment and should not be confounded with (life-long) suppressive therapy
per se. Hence, we cannot pronounce on this latter group due to paucity of cases. Second, in our
cohort, the median number of surgical interventions was two. This is higher than most author groups
advocate [2,15,26–28,31,33], reporting only one debridement in their DAIR approach (with or without
exchange of mobile parts). Moojen et al. specifically investigated this question and concluded that
a single debridement, with additional surgery on indication, appears to be at least as successful for
DAIR than multiple debridements [3]. We found one publication advocating that 1 single debridement
was not sufficient. This is, however, a study of 43 PJIs exclusively due to MRSA [25]. Third, no
specific antibiotic regimens, e.g., the combination with rifampicin [34] or ciprofloxacin [35], or specific
pathogens such as S. aureus [11,15,16,23,31] or Pseudomonas aeruginosa [27,32], were associated with
altered remission rates. This can be related to the small sample size of the individual strata. For
example, enterococcal DAIR might have a worse outcome according to clinical personal experience
of many expert groups [39], which we, however, cannot prove with only six own cases. Fourth, we
analyzed the mobile parts’ exchange as a dichotomous parameter (done versus not done within a
“black box” approach). We ignored details regarding the intervention, its duration, and unreported
complications. The experience of the surgical team and the individual operation course might play
a role that we cannot include in our final analysis. Fifth, we focus on infection remission and not
on functional outcome. The role of the exchange of mobile parts regarding immediate or long-term
mechanical sequelae, embedded in a wide range of case-mix, is statistically difficult to determine [28]
and probably only feasible within a prospective trial that is specially designed for that question. Sixth,
the median follow-up time was 3.3 years, but the minimum was six months. In the literature of
implant-related orthopedic infections the follow up time is usually one year, in terms of occurrence
of infection [5], and it is usually 1–2 years after the treatment of PJI by the one- or two-change
exchange [11]. However, concerning DAIR, the ideal active follow-up time is less clearly advocated in
the literature, and persistence or recurrence of clinical infection (failure) is usually witnessed much
earlier compared to exchange procedures [1]. We therefore conducted a side analysis with episodes
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harboring an active clinical follow-up of at least two years and found very similar results. Finally,
although 18 different key variables such as pertinent demographics (sex, age, American Society of
Anesthesiologist’s Score (ASA-Score)), material (type of prosthesis, revision), infection (pathogens,
pain, bacteremia) and therapy (antibiotic durations, administrations and combinations, number and
type of surgeries) have been assessed in the multivariable analyses, there are still others which we
could not include to avoid “statistical model overfitting” such as the KLIC-Score (Kidney, Liver, Index
surgery, Cemented prosthesis and C-reactive protein value) [30] or femoral neck fractures. Likewise,
materials are important. We simply could not consider all materials individually in the pre-operative
and post-operative settings (e.g., cement, different metals, which theoretically may influence the
pre-operative risks and the post-operative outcomes).
In conclusion, changing of mobile parts during DAIR likely increases the chance of long-term
remission (doubling the hazard ratio in our study). As usual, we call for caution in the interpretation of
our retrospective study data. For example, some relevant information to help clinical decision-making
may be lacking, and our survivor analysis mainly highlights the first-year impact of the DAIR
approach. We personally consider this exchange imperative and certainly more important than any
antibiotic-related or demographic parameters. Nevertheless, because of the controversy in published
literature, a well-designed meta-analysis (or “Cochrane review”) still remains warranted. [40]
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